GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Feedback PLC (LSE:FDBK) » Definitions » ROCE %

Feedback (LSE:FDBK) ROCE % : -43.05% (As of Nov. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Feedback ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Feedback's annualized ROCE % for the quarter that ended in Nov. 2023 was -43.05%.


Feedback ROCE % Historical Data

The historical data trend for Feedback's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feedback ROCE % Chart

Feedback Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -146.44 -102.13 -58.43 -26.48 -27.85

Feedback Semi-Annual Data
May14 Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.76 -17.94 -24.88 -30.98 -43.05

Feedback ROCE % Calculation

Feedback's annualized ROCE % for the fiscal year that ended in May. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: May. 2023 )  (A: May. 2022 )(A: May. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: May. 2023 )  (A: May. 2022 )(A: May. 2023 )
=-3.422/( ( (14.303 - 0.594) + (11.724 - 0.855) )/ 2 )
=-3.422/( (13.709+10.869)/ 2 )
=-3.422/12.289
=-27.85 %

Feedback's ROCE % of for the quarter that ended in Nov. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Nov. 2023 )  (Q: May. 2023 )(Q: Nov. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Nov. 2023 )  (Q: May. 2023 )(Q: Nov. 2023 )
=-4.27/( ( (11.724 - 0.855) + (9.883 - 0.914) )/ 2 )
=-4.27/( ( 10.869 + 8.969 )/ 2 )
=-4.27/9.919
=-43.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Nov. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Feedback  (LSE:FDBK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Feedback ROCE % Related Terms

Thank you for viewing the detailed overview of Feedback's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Feedback (LSE:FDBK) Business Description

Traded in Other Exchanges
Address
3-7 Temple Avenue, 201 Temple Chambers, London, GBR, EC4Y 0DT
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. The company also entered into a joint venture for future clinical application of its products on patients with kidney stones and it has a medical imaging segment.

Feedback (LSE:FDBK) Headlines

No Headlines